QPPV.COM KNOWLEDGE ASSESSMENT

Anifrolumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Anifrolumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement about the benefit-risk assessment of anifrolumab is most accurate?

Benefit should be represented by a single interferon-related laboratory marker Infection risk should be attributed entirely to anifrolumab without considering SLE or concomitant therapy Benefit-risk assessment should balance reduction of clinically important SLE activity against contextualised infection, zoster, hypersensitivity and route-related risks Route expansion changes the molecular mechanism and therefore invalidates all previous safety knowledge

Question 2 of 10 Which set of information is most useful for evaluating suspected lupus flare rather than relying solely on symptom terms?

Baseline organ involvement, objective disease measures, complement and anti-dsDNA trends, infection exclusion and treatment changes Only the patient's report that symptoms feel similar to a previous flare Only the date of the last anifrolumab shipment The colour and size of the injection device

Question 3 of 10 A patient develops fever, rash and arthralgia during anifrolumab treatment. What is the most appropriate initial pharmacovigilance interpretation?

The event should automatically be classified as a lupus flare The event should automatically be classified as anaphylaxis The symptoms should be assessed against flare, infection, hypersensitivity and treatment-related alternatives The symptoms cannot be relevant to pharmacovigilance because they are common in SLE

Question 4 of 10 Which scenario most clearly illustrates why treatment interruption and response can help distinguish competing explanations for an event?

A patient has an isolated historical diagnosis with no current symptoms Symptoms arise after dosing, improve after treatment changes and are accompanied by objective findings that clarify flare, infection or hypersensitivity A device is stored according to instructions and no dose is missed A patient has stable disease and no adverse event

Question 5 of 10 A patient reports that a pre-filled pen malfunctioned and only part of the dose was delivered, followed by worsening SLE symptoms. What is the most appropriate case interpretation?

Record only lack of efficacy because device events are not pharmacovigilance issues Assume biological resistance to anifrolumab Capture the device problem, delivered dose, clinical consequence and possible missed or incomplete exposure Classify the event as an infusion reaction

Question 6 of 10 A patient receiving substantial corticosteroid therapy develops pneumonia shortly after anifrolumab initiation. Which conclusion is most scientifically defensible?

The timing proves anifrolumab was the sole cause The event cannot be related to anifrolumab because corticosteroids are present The case requires multifactorial assessment incorporating anifrolumab, corticosteroid exposure, SLE activity and infection characteristics The event should be coded as lupus flare because pneumonia is common in SLE

Question 7 of 10 What is the principal pharmacovigilance significance of the later addition of subcutaneous anifrolumab presentations?

It changes IFNAR1 into a different molecular target It eliminates the need to monitor infusion reactions It introduces additional risks involving self-administration, injection sites, devices, storage and missed doses It proves that all adverse reactions are more frequent with subcutaneous treatment

Question 8 of 10 Which distinction is most important when reviewing a suspected subcutaneous hypersensitivity report?

Local injection-site findings should be distinguished from systemic hypersensitivity, while documenting timing, presentation and self-administration circumstances All local reactions should be considered evidence of anaphylaxis Only systemic symptoms matter; the injection site and device can be ignored Subcutaneous reactions should be analysed as infusion reactions because the active substance is identical

Question 9 of 10 Which inspection or quality-review question best tests whether the pharmacovigilance system has adapted to the subcutaneous lifecycle expansion?

Does the system remove all intravenous cases from the database? Does the system preserve route, presentation and device information and distinguish injection or device events from systemic reactions? Does the system treat every injection-site event as anaphylaxis? Does the system stop collecting background immunosuppressive treatment?

Question 10 of 10 Which data structure best supports analysis of herpes zoster severity in an anifrolumab safety database?

A single undifferentiated herpes-zoster preferred term with no clinical detail Separate information on localisation or dissemination, dermatome, neurological or ophthalmic involvement, treatment and outcome Only the date on which anifrolumab was first prescribed Only whether the patient was receiving a corticosteroid at any time in the past

Anifrolumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance

Cookie Settings